

Magid A Abou-Gharbia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1208698/publications.pdf>

Version: 2024-02-01

80
papers

2,758
citations

201674

27
h-index

189892

50
g-index

84
all docs

84
docs citations

84
times ranked

4155
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. <i>Cell</i> , 2018, 175, 1244-1258.e26.	28.9	182
2	Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. <i>Cell Reports</i> , 2016, 16, 1273-1286.	6.4	165
3	Tiplaxtinin, a Novel, Orally Efficacious Inhibitor of Plasminogen Activator Inhibitor-1: Design, Synthesis, and Preclinical Characterization. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 3491-3494.	6.4	162
4	Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein β -Secretase for the Treatment of Alzheimer's Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 598-608.	2.5	147
5	Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole Estrogens. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1654-1657.	6.4	135
6	Enhanced clearance of $A\beta$ in brain by sustaining the plasmin proteolysis cascade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8754-8759.	7.1	123
7	Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 33-38.	7.1	115
8	Discovery of Begacestat, a Notch-1-Sparing β -Secretase Inhibitor for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7348-7351.	6.4	104
9	Estrogen Receptor Antagonists Are Anti-Cryptococcal Agents That Directly Bind EF Hand Proteins and Synergize with Fluconazole <i>In Vivo</i> . <i>MBio</i> , 2014, 5, e00765-13.	4.1	91
10	Comparison of Human and Rat Uterine Leiomyomata: Identification of a Dysregulated Mammalian Target of Rapamycin Pathway. <i>Cancer Research</i> , 2009, 69, 6171-6178.	0.9	89
11	Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer. <i>Cancer Research</i> , 2016, 76, 1494-1505.	0.9	88
12	Synthesis and SAR of Adatanserin: A Novel Adamantyl Aryl- and Heteroaryl piperazines with Dual Serotonin 5-HT _{1A} and 5-HT _{2A} Activity as Potential Anxiolytic and Antidepressant Agents. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5077-5094.	6.4	82
13	Design and Synthesis of [2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic Acid (EAA-090), a Potent N-Methyl-D-Aspartate Antagonist, via the Use of 3-Cyclobutene-1,2-dione as an Achiral β -Amino Acid Bioisostere. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 236-246.	6.4	71
14	Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids. <i>Carcinogenesis</i> , 1981, 2, 717-721.	2.8	66
15	12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice. <i>Biological Psychiatry</i> , 2017, 81, 92-100.	1.3	66
16	Antipsychotic activity of substituted γ -carbolines. <i>Journal of Medicinal Chemistry</i> , 1987, 30, 1818-1823.	6.4	51
17	Design, Synthesis, SAR, and Biological Evaluation of Highly Potent Benzimidazole-Spaced Phosphono- β -Amino Acid Competitive NMDA Antagonists of the AP-6 Type. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1516-1529.	6.4	49
18	Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 681-695.	6.4	48

#	ARTICLE	IF	CITATIONS
19	Dehydroepiandrosterone and 16 β -bromo-epiandrosterone: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes. <i>Carcinogenesis</i> , 1981, 2, 683-686.	2.8	44
20	New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D2 Agonist Pharmacophore. Structure-Activity Relationships of a Series of 2-(Aminomethyl)chromans. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 4235-4256.	6.4	44
21	Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 2. Pharma's Challenges and Their Commitment to Innovation. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5525-5553.	6.4	43
22	Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 1024-1033.	6.4	42
23	Polycyclic aryl- and heteroaryl piperazinyl imides as 5-HT _{1A} receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. <i>Journal of Medicinal Chemistry</i> , 1988, 31, 1382-1392.	6.4	38
24	Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7719-7725.	2.2	38
25	Prodrugs of Perzinfotel with Improved Oral Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 771-778.	6.4	31
26	Chapter 1. Sigma Receptors and their Ligands: The Sigma Enigma. <i>Annual Reports in Medicinal Chemistry</i> , 1993, 28, 1-10.	0.9	30
27	Discovery of Innovative Small Molecule Therapeutics. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2-9.	6.4	30
28	Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1148-1155.	3.0	30
29	Emerging From the Unknown: Structural and Functional Features of Agnoprotein of Polyomaviruses. <i>Journal of Cellular Physiology</i> , 2016, 231, 2115-2127.	4.1	28
30	The Resurrection of Phenotypic Drug Discovery. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1820-1828.	2.8	26
31	Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: <i>In Silico</i> Modeling and <i>In Vitro</i> Screening. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 1020-1032.	5.4	25
32	Cycloaddition of ketenes with N-fluorenylidenealkylamine and -arylamine oxides. Synthesis of spirooxazolidinones and spiroisoxazolidinones. <i>Journal of Organic Chemistry</i> , 1979, 44, 2961-2966.	3.2	22
33	Tetrahydropyrrolo[1,2-a]quinoxalines and tetrahydropyrrolo[1,2-a]pyrido[3,2-a]pyrazines: vascular smooth muscle relaxants and antihypertensive agents. <i>Journal of Medicinal Chemistry</i> , 1984, 27, 1743-1746.	6.4	22
34	Reactions of ketenes with sulfilimines. Synthetic routes to oxazolinones and indolinones. <i>Journal of Organic Chemistry</i> , 1985, 50, 2224-2228.	3.2	22
35	Nuclear Magnetic Resonance Structure Revealed that the Human Polyomavirus JC Virus Agnoprotein Contains an α -Helix Encompassing the Leu/Ile/Phe-Rich Domain. <i>Journal of Virology</i> , 2014, 88, 6556-6575.	3.4	21
36	New generation dopaminergic agents 4. Exploiting the 2-methyl chroman scaffold. Synthesis and evaluation of two novel series of 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano[2,3-e]indole and indol-8-one derivatives. <i>Tetrahedron</i> , 1998, 54, 7081-7108.	1.9	20

#	ARTICLE	IF	CITATIONS
37	New generation dopaminergic agents. 2. Discovery of 3-OH-phenoxyethylamine and 3-OH-N1-phenylpiperazine dopaminergic templates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 295-300.	2.2	20
38	Synthesis and Biological Evaluation of Benzodioxanyl piperazine Derivatives as Potent Serotonin 5-HT _{1A} Antagonists: The Discovery of Lecozotan. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3467-3470.	6.4	20
39	Small-Molecule Inhibitors of <i>Staphylococcus aureus</i> RnpA-Mediated RNA Turnover and tRNA Processing. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2016-2028.	3.2	17
40	A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. <i>Oncotarget</i> , 2017, 8, 112184-112198.	1.8	17
41	Psychotropic agents: synthesis and antipsychotic activity of substituted .beta.-carbolines. <i>Journal of Medicinal Chemistry</i> , 1987, 30, 1100-1105.	6.4	15
42	The Synthesis and Biological Evaluation of Quinolyl-piperazinyl Piperidines as Potent Serotonin 5-HT _{1A} Antagonists. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4066-4084.	6.4	14
43	Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5352-5359.	3.0	14
44	Synthesis of rapamycin glycoconjugates via a CuAAC-based approach. <i>Tetrahedron Letters</i> , 2013, 54, 6999-7003.	1.4	12
45	Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 1. Criticisms Faced by the Pharmaceutical Industry. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5659-5672.	6.4	12
46	Discovery of Novel Small-Molecule Inhibitors of SARS-CoV-2 Main Protease as Potential Leads for COVID-19 Treatment. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4745-4757.	5.4	12
47	Synthesis of N-nitrosocimetidine hydrate and nitrate and tritium-labeling studies. <i>Journal of Organic Chemistry</i> , 1981, 46, 2193-2194.	3.2	11
48	Novel inhibitors of <i>Staphylococcus aureus</i> RnpA that synergize with mupirocin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1127-1131.	2.2	11
49	Be Back: The Resurrection of Dezocine. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 961-968.	2.8	11
50	Reaction of N-acylsulfilimines with diphenyl ketene. A new synthesis of 2-oxazolin-4-ones. <i>Tetrahedron Letters</i> , 1983, 24, 2811-2814.	1.4	10
51	Metabolism of N ^G -monomethyl-L-arginine. <i>Canadian Journal of Biochemistry and Cell Biology</i> , 1983, 61, 850-855.	1.3	10
52	New Antihistamines: Substituted Piperazine and Piperidine Derivatives as Novel H ₁ -Antagonists. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 4026-4032.	6.4	10
53	Design, synthesis, and evaluation of (2S,4R)-Ketoconazole sulfonamide analogs as potential treatments for Metabolic Syndrome. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5825-5829.	2.2	10
54	Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3K/mTOR inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3117-3122.	2.2	10

#	ARTICLE	IF	CITATIONS
55	Oleic acid reinforced PEGylated polymethacrylate transdermal film with enhanced antidyslipidemic activity and bioavailability of atorvastatin: A mechanistic ex-vivo/in-vivo analysis. <i>International Journal of Pharmaceutics</i> , 2021, 608, 121057.	5.2	10
56	Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 1895-1900.	2.2	9
57	Nuclear Magnetic Resonance Structure of the Human Polyoma JC Virus Agnoprotein. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3268-3280.	2.6	9
58	Design and synthesis of functionalized piperazin-1-yl-(E)-stilbenes as inhibitors of 17 β -hydroxylase-C17,20-lyase (Cyp17). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2270-2274.	2.2	8
59	Discovery and SAR of Novel Disubstituted Quinazolines as Dual PI3K α /mTOR Inhibitors Targeting Breast Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2156-2164.	2.8	8
60	Synthesis of Spirofluorenes of Biological Interest. <i>Journal of Pharmaceutical Sciences</i> , 1978, 67, 953-956.	3.3	7
61	Synthesis of Dehydroepiandrosterone Sulfatide and 16 β -Halogenated Steroids. <i>Journal of Pharmaceutical Sciences</i> , 1981, 70, 1154-1157.	3.3	7
62	Behavioral pharmacology of the gamma carboline Wy 47,384: A potential antipsychotic agent. <i>Drug Development Research</i> , 1988, 13, 11-28.	2.9	7
63	A new and efficient synthetic route for the anxiolytic agent CL285032. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 259-261.	2.2	7
64	Chapter 1. Novel Antipsychotic Agents. <i>Annual Reports in Medicinal Chemistry</i> , 1990, 25, 1-10.	0.9	6
65	MC-100093, a Novel β -Lactam Glutamate Transporter-1 Enhancer Devoid of Antimicrobial Properties, Attenuates Cocaine Relapse in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 51-59.	2.5	6
66	Synthesis and Hydrolysis of Fluorene-9-spiro-2 β -(N-aryl-3,3-dichloroaziridines). <i>Journal of Pharmaceutical Sciences</i> , 1977, 66, 1653-1655.	3.3	5
67	AN IMPROVED SYNTHESIS OF FLUORENONE METHYLNITRONE. <i>Organic Preparations and Procedures International</i> , 1979, 11, 95-96.	1.3	5
68	WAY-131256 is an orally active, efficacious, and in vivo functionally selective M1 agonist. <i>Drug Development Research</i> , 1997, 40, 185-192.	2.9	5
69	Targeting neurodegenerative diseases: Drug discovery in a challenging arena. <i>Pure and Applied Chemistry</i> , 2012, 84, 1543-1556.	1.9	5
70	Reaction of <i>tert</i> -Butylcyanoketene with 2 β -Cyclohexylspiro [Fluorene-9,3 β -Oxaziridine]. <i>Synthetic Communications</i> , 1979, 9, 871-876.	2.1	4
71	Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 42, 116251.	3.0	4
72	Preclinical profile of Wy-49,051: A new H1-antagonist. <i>Drug Development Research</i> , 1990, 21, 63-78.	2.9	3

#	ARTICLE	IF	CITATIONS
73	Novel compounds that reverse the disease phenotype in Type 2 Gaucher disease patient-derived cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126806.	2.2	3
74	Mass spectra of nitrones. Electron impact mass spectra of fluorenone nitrones. <i>Journal of Chemical & Engineering Data</i> , 1981, 26, 216-218.	1.9	2
75	Epiandrosterone- and Dehydroepiandrosterone-3 ^{Î²} -alkanesulfonates as Inhibitors of Mouse Glucose-6-phosphate Dehydrogenase Activity. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 1643-1645.	3.3	2
76	The mass spectra of fluorenone nitrones. <i>Organic Mass Spectrometry</i> , 1980, 15, 489-490.	1.3	1
77	A NEW SYNTHESIS OF 2-BROMO-1-(9-PHENANTHRYL)ETHANE. <i>Organic Preparations and Procedures International</i> , 1985, 17, 195-198.	1.3	1
78	A Novel Assay Platform for the Detection of Translation Modulators of Spermidine/ Spermine Acetyltransferase. <i>Current Pharmaceutical Design</i> , 2014, 20, 245-252.	1.9	1
79	Binding of novel rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. <i>FASEB Journal</i> , 2008, 22, 619-619.	0.5	1
80	Facile synthesis of the glucosylceramide synthase inhibitor GZ667161. <i>Tetrahedron Letters</i> , 2020, 61, 152352.	1.4	0